VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Saturday, January 3, 2026

Stock Comparison

Bureau Veritas S.A. vs Novartis AG

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

Bureau Veritas S.A.

BVI · Euronext Paris

Market cap (USD)$11.8B
Gross margin (TTM)22.7%
Operating margin (TTM)14%
Net margin (TTM)9.3%
SectorIndustrials
IndustryConsulting Services
CountryFR
Data as of2025-12-28
Moat score
66/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Bureau Veritas S.A.'s moat claims, evidence, and risks.

View BVI analysis

Novartis AG

NOVN · SIX Swiss Exchange

Market cap (USD)
Gross margin (TTM)
Operating margin (TTM)
Net margin (TTM)
SectorHealthcare
Industry
CountryCH
Data as of2026-01-02
Moat score
65/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Novartis AG's moat claims, evidence, and risks.

View NOVN analysis

Comparison highlights

  • Moat score gap: Bureau Veritas S.A. leads (66 / 100 vs 65 / 100 for Novartis AG).
  • Segment focus: Bureau Veritas S.A. has 6 segments (29.3% in Buildings & Infrastructure); Novartis AG has 5 segments (29.3% in Oncology).
  • Primary market structure: Competitive vs Oligopoly. Pricing power: Moderate vs Strong.
  • Moat breadth: Bureau Veritas S.A. has 6 moat types across 3 domains; Novartis AG has 4 across 3.

Primary market context

Bureau Veritas S.A.

Buildings & Infrastructure

Market

Construction, buildings and infrastructure inspection/testing and project assurance

Geography

Global

Customer

Developers, contractors, infrastructure operators, public authorities

Role

Third-party testing/inspection and compliance verification across project lifecycle

Revenue share

29.3%

Novartis AG

Oncology

Market

Oncology and hematology branded medicines (including targeted therapies and radioligand therapy)

Geography

Global

Customer

Oncologists and hospitals; reimbursed by payers; hospital and specialty pharmacy channels

Role

Originator developer, manufacturer, and marketer of oncology therapies

Revenue share

29.3%

Side-by-side metrics

Bureau Veritas S.A.
Novartis AG
Ticker / Exchange
BVI - Euronext Paris
NOVN - SIX Swiss Exchange
Market cap (USD)
$11.8B
n/a
Gross margin (TTM)
22.7%
n/a
Operating margin (TTM)
14%
n/a
Net margin (TTM)
9.3%
n/a
Sector
Industrials
Healthcare
Industry
Consulting Services
n/a
HQ country
FR
CH
Primary segment
Buildings & Infrastructure
Oncology
Market structure
Competitive
Oligopoly
Market share
n/a
n/a
HHI estimate
n/a
n/a
Pricing power
Moderate
Strong
Moat score
66 / 100
65 / 100
Moat domains
Legal, Supply, Demand
Legal, Supply, Demand
Last update
2025-12-28
2026-01-02

Moat coverage

Shared moat types

Regulated Standards PipeCapex Knowhow Scale

Bureau Veritas S.A. strengths

Service Field NetworkProcurement InertiaOperational ExcellenceSwitching Costs General

Novartis AG strengths

IP Choke PointBrand Trust

Segment mix

Bureau Veritas S.A. segments

Full profile >

Marine & Offshore

Oligopoly

8.1%

Agri-Food & Commodities

Competitive

20.3%

Industry

Competitive

21.1%

Buildings & Infrastructure

Competitive

29.3%

Certification

Competitive

8.4%

Consumer Products Services

Competitive

12.8%

Novartis AG segments

Full profile >

Cardiovascular, Renal and Metabolic

Oligopoly

17%

Immunology

Oligopoly

18.5%

Neuroscience

Oligopoly

9.4%

Oncology

Oligopoly

29.3%

Established Brands

Competitive

25.8%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.